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ABSTRACT
Objectives: The STarT Back Tool has good predictive
performance for non-specific low back pain in primary
care. We therefore aimed to investigate whether a
modified STarT Back Tool predicted outcome with a
broader group of musculoskeletal patients, and
assessed the consequences of using existing risk-
group cut-points across different pain regions.
Setting: Secondary analysis of prospective data from
2 cohorts: (1) outpatient musculoskeletal
physiotherapy services (PhysioDirect trial n=1887) and
(2) musculoskeletal primary–secondary care interface
services (SAMBA study n=1082).
Participants: Patients with back, neck, upper limb,
lower limb or multisite pain with a completed modified
STarT Back Tool (baseline) and 6-month physical
health outcome (Short Form 36 (SF-36)).
Outcomes: Area under the receiving operator curve
(AUCs) tested discriminative abilities of the tool’s
baseline score for identifying poor 6-month outcome
(SF-36 lower tertile Physical Component Score). Risk-
group cut-points were tested using sensitivity and
specificity for identifying poor outcome using (1)
Youden’s J statistic and (2) a clinically determined rule
that specificity should not fall below 0.7 (false-positive
rate <30%).
Results: In PhysioDirect and SAMBA, poor 6-month
physical health was 18.5% and 28.2%, respectively.
Modified STarT Back Tool score AUCs for predicting
outcome in back pain were 0.72 and 0.79, neck 0.82
and 0.88, upper limb 0.79 and 0.86, lower limb 0.77
and 0.83, and multisite pain 0.83 and 0.82 in
PhysioDirect and SAMBA, respectively. Differences
between pain region AUCs were non-significant.
Optimal cut-points to discriminate low-risk and
medium-risk/high-risk groups depended on pain region
and clinical services.
Conclusions: A modified STarT Back Tool similarly
predicts 6-month physical health outcome across 5
musculoskeletal pain regions. However, the use of
consistent risk-group cut-points was not possible and
resulted in poor sensitivity (too many with long-term
disability being missed) or specificity (too many with
good outcome inaccurately classified as ‘at risk’) for
some pain regions. The draft tool is now being refined
and validated within a new programme of research for
a broader musculoskeletal population.
Trial registration number: ISRCTN55666618;
Post results.
INTRODUCTION
The Keele STarT Back Tool is designed to
stratify patients with low back pain according
to their risk of future physical disability, in
order that prognostic subgroups can receive
matched treatment.1 For example, indivi-
duals at a low risk of persistent disabling pro-
blems can be reassured and discouraged
from receiving unnecessary treatments and
investigations, while those at high risk can
matched to treatment which combines phys-
ical and psychological approaches.2–4 A large
randomised trial testing a risk stratiﬁcation
approach (use of the STarT Back Tool and
matched treatments) for low back pain in
comparison to best current care
Strengths and limitations of this study
▪ First study to demonstrate that modified STarT
Back Tool items are similarly predictive of
6-month physical health across different muscu-
loskeletal pain regions.
▪ Within two large independent cohorts it was
consistently shown that a modified STarT Back
Tool similarly predicts 6-month physical health
outcome in other musculoskeletal pain regions
as well as low back pain.
▪ A limitation of the study was that the original
STarT Back Tool was not included in these two
data sets, so a direct comparison between the
performance of the original and modified STarT
Back Tool versions for patients with low back
pain was not possible.
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demonstrated superior clinical and cost outcomes.5 In
addition, an implementation study testing risk stratiﬁca-
tion for patients with low back pain in routine general
practice demonstrated signiﬁcant improvements in phys-
ical function and time off work, sickness certiﬁcation
rates and reductions in healthcare costs compared to
usual non-stratiﬁed care.2 Since low back pain accounts
for only 17% of all UK primary care musculoskeletal
consultations in general practice,6 if a similar screening
tool could be used for patients with other common pain
presentations, such as neck pain and knee pain, then
there could be potential for stratiﬁed care to make a
greater impact for patients and healthcare services.
A previous systematic review of 45 cohort studies7
reported that prognostic factors are often similar across
different musculoskeletal presentations, with 11 factors
predicting poor outcome at follow-up for at least two dif-
ferent musculoskeletal pain problems. Other studies
have similarly shown that a generic set of baseline
factors (pain intensity, episode duration, pain interfer-
ence, depression and comorbid pain problems) predicts
risk of a poor outcome across different pain regions,
including back pain, headache, facial pain and knee
pain, regardless of the speciﬁc location of pain or under-
lying pathology.8–12 These studies indicate that it might
be possible to use the same prognostic factors as those
included within the STarT Back Tool to discriminate risk
status for a much larger group of musculoskeletal pain
patients than those consulting with low back pain. The
key beneﬁt of using a single tool to stratify patients with
a wide range of musculoskeletal conditions rather than
multiple site-speciﬁc prognostic screening tools is its sim-
plicity for use in busy clinical practice.
While the likely value and acceptability of extending
risk stratiﬁcation to patients with other common musculo-
skeletal pain is as yet unknown, evidence suggests that the
majority of general practitioners (GPs) consider prognosis
to be important in their clinical decision-making for mus-
culoskeletal treatment.13 Despite the widespread support
for prognostic information, the clinical reality is that pre-
dicting outcome in these patients is not always easy and
patient’s risk status is not typically included within
medical records.14 GPs are not alone in wanting informa-
tion about patients’ likely prognosis over time, as >80% of
musculoskeletal patients also want prognostic information
from their GP, although less than a third actually receive
this information.14 Existing musculoskeletal prognostic
tools are available (eg, Linton and Hallden15 and Von
Korff et al).16 17 However, these prognostic tools were not
designed or tested to support clinical decisions in primary
care about matched treatments (stratiﬁed care); only the
STarT Back Tool has been speciﬁcally developed and
tested to guide patient treatment matching.
The aim of this study was therefore to investigate the
performance of a modiﬁed STarT Back Tool for predict-
ing future physical health outcome for a broader group
of musculoskeletal pain patients. Speciﬁc objectives were
to compare the predictive performance of a modiﬁed
STarT Back Tool for patients with musculoskeletal pain
in different body regions and assess the consequences
(false-positive and false-negative rates) of using existing
STarT Back Tool score cut-points for classifying patients
as medium/high risk across different pain regions
(neck, back, upper limb, lower limb and multisite pain).
METHODS
Design
This study involved prespeciﬁed further analysis of exist-
ing data sets from two prospective cohorts of adults with
musculoskeletal conditions consulting in two different
services in the National Health Service, UK. Full ethical
approval for both these studies was obtained and
patients provided written informed consent prior to
their research participation.
Patient population
1. The PhysioDirect trial included 2249 adult musculo-
skeletal patients taking part in a randomised trial com-
paring a PhysioDirect service (telephone-based
physiotherapy assessment and advice) with usual
physiotherapy care.18–20 Primary outcome data (phys-
ical health measured using the SF-36v2 physical com-
ponent score) at 6-month follow-up and baseline
modiﬁed STarT Back Tool score were available for
1887 patients (84%) and were included in this analysis.
The trial was conducted in four NHS community
physiotherapy services in four different areas of
England (Bristol, Somerset, Stoke-on-Trent and
Cheshire). Adults (aged ≥18 years) who were referred
by 94 GPs (covering a wide range of geographical areas
and populations), or who referred themselves for
physiotherapy for a musculoskeletal problem, were eli-
gible for the trial. Patients completed postal question-
naires at baseline and 6 months after randomisation.
Details about the PhysioDirect patient sample have
been published.18 For the study reported here, we used
patients from the control and intervention arms.
2. The SAMBA study was an observational cohort of
adults attending an NHS musculoskeletal clinical
assessment and treatment service at the primary–sec-
ondary care interface.21 22 The study population
included 2166 patients referred from primary care and
subsequently triaged to musculoskeletal and back pain
interface clinics in Stoke-on-Trent Primary Care Trust
(PCT) over a 12-month period. Primary outcome data
at 6-month follow-up (physical health measured using
the SF-36v2 physical component score) and the modi-
ﬁed STarT Back Tool score at baseline were available
for 1082 patients (50%) who formed the study popula-
tion for this evaluation. All adults (aged ≥18 years)
capable of giving written informed consent were eli-
gible to participate in the study. Patients completed
study questionnaires before their ﬁrst appointment
during which consent was obtained and 6 month after
that initial clinic appointment. Details of the SAMBA
study sample have been published.22
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Modifying the STarT Back Tool
The original STarT Back Tool includes nine items of
which ﬁve concern psychosocial factors (fear, catastro-
phising, anxiety, depression and bothersomeness). The
PhysioDirect trial and SAMBA study included the STarT
Back Tool’s psychosocial items within their baseline ques-
tionnaires.1 These items were used without modiﬁcation
as they were developed from generic tools and are not
speciﬁc to low back pain. However, the four further items
of the original STarT Back Tool that capture three phys-
ical factors (referred pain from the back down the leg,
comorbid pain in the neck and shoulder, and physical
function with walking and dressing items) are speciﬁc to
low back pain and therefore these items in their original
form needed to be replaced by similar items that were
applicable for all musculoskeletal patients. We therefore
used proxy items for these outcome domains that were
available in both data sets. The STarT Back Tool’s two
‘function’ items (walking and dressing) were replaced by
items from the generic EQ-5D23 (‘I have some problems
in walking about’, Y/N and ‘I have some problems
washing or dressing myself’, Y/N), and we used item 7
from the SF-1224 (‘How much bodily pain have you had?’
with positive responses deﬁned as ‘extremely’ or ‘very
severe’) instead of the original STarT Back Tool item for
comorbid pain in the neck or shoulder. It was not pos-
sible to replace ‘referred pain from the back down the
leg’ with an item that was suitable for all musculoskeletal
pain and so this construct of the ‘spread of pain’ was
omitted from the modiﬁed tool. To score the modiﬁed
STarT Back Tool, responses from these eight items were
summed (range 0–8) for all patients in both data sets.
The original STarT Back Tool cut-off of 0–3 positive
items was used to classify patients as at low risk and 4 or
more as at medium or high risk. There were no reference
standards for psychological distress in either the
PhysioDirect or SAMBA data sets and so in this analysis
we did not seek to examine the ability of the modiﬁed
STarT Back Tool to identify a high-risk-only group. We
believe that there is a strong clinical rationale for identify-
ing musculoskeletal cases that are ‘at risk’ of a poor prog-
nosis, which reﬂects the combined medium-risk and
high-risk subgroup. In our previous IMPaCT Back study2
implementing risk stratiﬁcation in general practice, the
clinicians used a 6-item STarT Back Tool which only dis-
criminated between low-risk and a combined medium-
risk/high-risk group to decide which patients to refer or
not to refer physiotherapy. In that study, the physiothera-
pists who received ‘at risk’ patients then used the full
9-item STarT Back Tool to discriminate the distressed
patients who needed a psychologically informed physio-
therapy treatment approach.
Defining the body regions of pain
Participants were asked to indicate the primary site of
their musculoskeletal pain for which they had sought
treatment. From this information, patients were cate-
gorised as having one of the following regional pain
problems: neck, back (thoracic or lumbar), upper limb,
lower limb or multisite pain (pain in more than one
region).
Defining physical health outcome
The standardised summary score for the Physical
Component Score (PCS) of the Short Form 36 (SF-36)
Health Survey is population normalised (0 is worst phys-
ical health and 100 is best physical health) and was clas-
siﬁed by tertiles (≤33, 34–66, >66) as has been used
previously25 26 with a 6-month poor outcome deﬁned
using the most severe tertile (≤33). Outcome was
deﬁned as poor physical health at 6-month follow-up
using the SF-36 PCS because this was the most appropri-
ate physical function outcome score available in both
studies, and it has demonstrated good validity and
responsiveness in this population.27–29
Statistical analysis
All analyses were conducted separately for the two data
sets and a descriptive comparison of the modiﬁed baseline
STarT Back Tool scores (mean and SD) and proportion
with poor 6-month physical health outcome (SF-36 PCS
≤33) calculated. Descriptive statistics using means and SDs
were used to examine the modiﬁed STarT Back Tool
score’s distribution and investigate potential ﬂoor or ceiling
effects (>10% of either lowest or maximum score).30
Predictive performance (discrimination) was assessed
by calculating ROC curve AUCs for baseline modiﬁed
STarT Back Tool total scores against 6-month poor physical
health outcome (dichotomised as poor/good) for each of
the ﬁve different bodily pain presentations and their equal-
ity compared using STATA’s ‘roccomp’ command to estab-
lish whether AUC differences were statistically signiﬁcant.
To examine whether the optimal subgroup cut-point
on the modiﬁed STarT Back Tool total score to discrim-
inate low from medium/high risk for poor 6-month
physical health outcome was consistent across the ﬁve
different pain regions and across the two data sets, we
used two methods based on sensitivity and speciﬁcity of
each potential cut-point. First, we used Youden’s J
Statistic which is calculated as sensitivity+speciﬁcity−1
for each potential cut-point and the optimal cut-point is
the tool score with the highest value.31 32 Second, we a
priori agreed that speciﬁcity should not fall below 0.7,
as lower values would mean potentially overtreating
>30% of medium-risk/high-risk patients, which was con-
sidered an unacceptable level for an efﬁcient matched
treatment approach.
In this study, we were not able to identify optimal sub-
group cut-points on the modiﬁed STarT Back Tool to
distinguish between medium-risk and high-risk patients
as there were no reference standards for psychological
distress in the two available data sets. The original STarT
Back Tool used these reference standards to identify dis-
tress ‘caseness’ at baseline, and identiﬁed the optimal
cut-point to screen for these distressed ‘cases’ using a
psychological subscale score. Without these reference
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standards for psychological distress, we were limited to
determining optimal subgroup cut-points on the total
scale score between low and medium/high risk alone.
RESULTS
Distribution of the modified STarT Back Tool scores in
both data sets
In the PhysioDirect trial sample (n=1887), the 8-item
modiﬁed STarT Back Tool score at baseline was normally
distributed with a mean (SD) of 3.35 (2.09); 8.4% had
the lowest score (0) and 2.2% had the maximum score
(8). The distribution of primary pain regions was
reported by clinicians as: lower limb 31.1%, back 28.7%,
upper limb 23.5%, neck 11.8% and multisite pain 4.8%.
The 6-month SF-36 PCS mean (SD) was 43.7 (10.9) with
18.5% having a ‘poor outcome’ in their physical health
at 6-month follow-up. The mean age was 48 years old
and 60% were female.
In the SAMBA study sample (n=1082), the 8-item
modiﬁed STarT Back Tool score at baseline was not nor-
mally distributed but had roughly equal numbers of all
possible scores with a mean (SD) of 3.95 (2.65); 12.6%
had the lowest score (0) and 10.9% had the maximum
score (8). The distribution of primary pain sites was
reported by patients as: lower limb 30.8%, back 26.7%,
upper limb 23.8%, multisite pain 13.4% and neck 5.4%.
The 6-month SF-36 PCS mean (SD) was 38.41 (12.76)
with 28.2% having a ‘poor outcome’ in their physical
health at 6-month follow-up. The mean age was 51 years
old and 57% were female.
Predictive performance of the modified STarT Back Tool
score across pain regions in both data sets
Predictive performance of the modiﬁed STarT Back
Tool as determined by ROC curve AUCs ranged from
0.72 to 0.83 and was not found to be statistically different
across different pain regions in the PhysioDirect trial
Figure 1 ROC curves for overall
modified STarT Back tool scores
against 6-month poor physical
health outcome (SF-36 PCS ≤33)
by different pain regions in the
PhysioDirect data set. AUC, area
under the receiving operator
curve; ROC, receiver operating
characteristic; SF-36,
Short Form 36.
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(p=0.098) and SAMBA study (p=0.130) (presented in
ﬁgures 1 and 2).
Optimal modified STarT Back Tool score cut-offs in both
data sets
Table 1 reports sensitivity, speciﬁcity and the Youden’s J
statistic for each possible modiﬁed STarT Back Tool
score cut-point at baseline for each pain region. The
results demonstrate that the optimal STarT Back Tool
baseline score cut-point for discriminating ‘poor
outcome’ at 6-month follow-up was not consistent across
pain regions. For example, among (PhysioDirect)
patients with neck, back and multisite pain, the optimal
STarT Back Tool cut-point for discriminating ‘poor
outcome’ was 5, whereas this was 4 for those with upper
limb and lower limb as their primary pain site.
DISCUSSION
This is the ﬁrst study to demonstrate that a modiﬁed
STarT Back Tool is similarly predictive of 6-month phys-
ical health (deﬁned by worst tertile of the SF-36) across
different musculoskeletal pain regions. Predictive per-
formance determined by AUCs for the 8-item modiﬁed
STarT Back Tool total score was in fact slightly higher
for neck, upper limb, lower limb and multisite pain than
for back pain, although differences were not statistically
signiﬁcant. The results therefore demonstrate that the
prognostic factors included within the STarT Back Tool
are predictive of 6-month physical health across a range
of musculoskeletal pain regions, not just back pain.
However, the results demonstrated that the optimal
baseline STarT Back Tool score cut-point for identifying
individuals with poor physical health outcome was
Figure 2 ROC curves for overall
modified STarT Back tool scores
against 6-month poor physical
health outcome (SF-36 PCS ≤33)
by different pain regions in the
SAMBA data set. AUC, area
under the receiving operator
curve; ROC, receiver operating
characteristic; SF-36,
Short Form 36.
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neither consistent across different pain regions nor
across clinical services (community physiotherapy ser-
vices (PhysioDirect trial)) and primary–secondary care
interface services (SAMBA study). This ﬁnding was con-
sistent regardless of method used to determine the
optimal modiﬁed STarT Back Tool score cut-point
(Youden’s J statistic or an a priori deﬁned maximum
false-positive rate of 30%). This implies that the existing
original STarT Back Tool score cut-point (4 or more out
of 9) used to allocate patients with low back pain to the
medium-risk/high-risk subgroups cannot simply be
applied to patients with other musculoskeletal pain pre-
sentations or in different clinical services. This is likely
to be due to differences in patient characteristics across
services such as episode duration, which is known to
inﬂuence the performance of the original STarT Back
Tool.33 It is also likely that individual modiﬁed STarT
Back Tool items are not equally applicable to patients
with pain in the ﬁve regions.34 For example, the item
about walking difﬁculties is likely to be less relevant and
therefore less predictive of physical health outcome for
patients with upper limb pain than for those with lower
limb or spinal pain. A key message from this study is the
value and importance of testing the capabilities of the
STarT Back Tool in different settings and patient popu-
lations and not presuming that existing primary care
subgroup cut-points will be the same in other groups. If
wider validity is demonstrated, this will help strengthen
the case for the general applicability of the tool.
The ﬁndings of this study concur with previous evi-
dence suggesting that the same set of prognostic vari-
ables can be used to estimate prognosis of patients with
different musculoskeletal pain presentations.7 15 17 The
STarT Back Tool uses biopsychosocial constructs known
to predict persistent disability among patients with low
back pain, such as: difﬁculty with walking and dressing,
pain elsewhere, fear avoidance, pain catastrophising,
anxiety and low mood.1 However, the STarT Back Tool is
not just a prognostic index, but is used to stratify patients
for different matched treatments. An important issue
Table 1 Identifying optimal modified STarT Back Tool cut-points for each pain region using (1) Youden’s J statistic and (2) a
clinically defined maximum specificity of 0.7
PhysioDirect trial data SAMBA study data
Pain region
Modified STarT Back
Tool cut-point Sens Spec Youden’s Sens Spec Youden’s
Neck 3 0.967 0.451 0.418 1 0.556 0.556
Neck 4 0.833 0.668 0.501 1 0.644 0.644
Neck 5 0.767 0.777* 0.544 0.769 0.756* 0.525
Neck 6 0.467 0.87* 0.337 0.615 0.867* 0.482
Neck 7 0.3 0.959* 0.259 0.538 0.911* 0.449
Neck 8 0.067 0.99* 0.057 0.462 0.956* 0.418
Back 3 0.903 0.329 0.232 0.987 0.333 0.32
Back 4 0.832 0.491 0.323 0.935 0.454 0.389
Back 5 0.708 0.652 0.36 0.857 0.546 0.403
Back 6 0.442 0.818* 0.26 0.792 0.686 0.478
Back 7 0.23 0.921* 0.151 0.558 0.821* 0.379
Back 8 0.088 0.979* 0.067 0.273 0.913* 0.186
Upper limb 3 0.882 0.538 0.42 0.907 0.576 0.483
Upper limb 4 0.711 0.72* 0.431 0.86 0.681 0.541
Upper limb 5 0.513 0.853* 0.366 0.791 0.79* 0.581
Upper limb 6 0.303 0.929* 0.232 0.674 0.848* 0.522
Upper limb 7 0.158 0.973* 0.131 0.581 0.933* 0.514
Upper limb 8 0.039 0.989* 0.028 0.163 0.976* 0.139
Lower limb 3 0.9 0.47 0.37 0.904 0.505 0.409
Lower limb 4 0.77 0.618 0.388 0.851 0.664 0.515
Lower limb 5 0.57 0.789* 0.359 0.754 0.771* 0.525
Lower limb 6 0.36 0.895* 0.255 0.64 0.86* 0.5
Lower limb 7 0.21 0.971* 0.181 0.43 0.93* 0.36
Lower limb 8 0.05 0.996* 0.046 0.237 0.972* 0.209
Multisite pain 3 0.933 0.443 0.376 0.946 0.434 0.38
Multisite pain 4 0.833 0.656 0.489 0.946 0.566 0.512
Multisite pain 5 0.733 0.787* 0.52 0.911 0.663 0.574
Multisite pain 6 0.567 0.902* 0.469 0.857 0.711* 0.568
Multisite pain 7 0.333 0.934* 0.267 0.643 0.771* 0.414
Multisite pain 8 0.1 0.984* 0.084 0.357 0.94* 0.297
Grey shaded row indicates Youden’s optimal score cut-point for predicting 6-month outcome.
*Specificity was >0.7 according to predefined clinical criteria.
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highlighted by this analysis is that if clinicians simply
modify the STarT Back Tool for use with other musculo-
skeletal pain patients, they are at risk of matching
patients to inappropriate treatments. It is also apparent
that future translation and validation studies of the
STarT Back Tool need to carefully consider adopting
the same STarT Back Tool score cut-points as used in
the original UK STarT Back Tool study1 without ﬁrst
testing if these cut-points are appropriate for their own
clinical populations. Based on these ﬁndings, our team
has begun to further reﬁne and validate an improved
stratiﬁcation tool—the Keele STarT MSK Tool—which
will be speciﬁcally designed for use with primary care
patients consulting with the ﬁve most common musculo-
skeletal pain presentations in a new programme of
research. While our study was not able to examine
optimal high-risk subgroup cut-offs for ‘distressed’
patients, a previous cross-sectional study34 in a US phys-
ical therapy population has compared the relationships
between a modiﬁed STarT Back Tool and psychological
measures in people with different pain regions. It is
found that regardless of body region of pain, higher
modiﬁed STarT Back Tool scores were associated with
higher levels of kinesiophobia, catastrophising, fear
avoidance, anxiety and depressive symptoms. The
strengths of our analyses reported here include the large
sample sizes of the PhysioDirect and SAMBA studies and
the opportunity to examine optimal cut-points in
patients with different pain sites and in different NHS
musculoskeletal services. An additional strength was that
both studies used the same measure of physical health
(SF-36), had the same 6-month follow-up time-point and
included patients whose pain could be classiﬁed into the
same musculoskeletal pain regions. Given the potential
weakness of using the Youden’s J Statistic to deﬁne
optimal cut-points for discriminating between low and
medium/high risk, we also used a clinically determined
guide (maximum false-positive rate), which showed
similar inconsistencies in optimal cut-off between
regional pain site and clinical setting. One weakness is
that the original STarT Back Tool was not included in
these two data sets, which meant a direct comparison
between the performance of the original and modiﬁed
versions for patients with low back pain was not possible.
The choice of poor physical health outcome at
6 months using the lowest tertile on the SF-12 was also
relatively arbitrary, but served the purpose of this analysis
to compare outcome between different regional pain
sites, making the exact deﬁnition of poor outcome less
critical to the study aims. It should be noted that the dif-
ferent levels of poor clinical outcome between the
PhysioDirect (18.5%) and Samba (28.2%) studies could
be due to the different settings and design of these two
studies and it is possible this may have inﬂuenced the
ﬁndings.
The implications from this analysis are that, despite
good predictive performance of the modiﬁed STarT
Back Tool in patients with pain in different regions of
the body, clinicians need to cautiously consider the
choice of cut-points when using a modiﬁed STarT Back
Tool for musculoskeletal pain regions other than low
back pain. The results suggest that existing cut-points
may lead to an inefﬁciency in healthcare resource use,
with too many patients with a likely long-term disability
being missed, or too many patients with good physical
health outcome being inaccurately classiﬁed as ‘at risk’,
which may result in over treatment of low-risk groups.
CONCLUSIONS
A modiﬁed version of the STarT Back Tool has similar
predictive performance when used for patients with mus-
culoskeletal pain in different body regions. However, the
cut-points used to identify patients with a poor physical
health outcome at 6-month follow-up are not consistent
across pain regions or clinical services. Further research
is underway to reﬁne and validate a new Keele STarT
MSK Tool which will form part of a new stratiﬁed care
approach to be tested in a randomised controlled trial.
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